2023-10-29 03:13:54
▲ Research results have shown that treatment resistance in metastatic castration-resistant prostate cancer can be overcome by preventing white blood cells from being ‘kidnapped’ into the tumor. (Photo = DB)
[메디컬투데이=최재백 기자] Research has shown that treatment resistance in metastatic castration-resistant prostate cancer can be overcome by preventing white blood cells from being hijacked into tumors.
Research results were published in the academic journal ‘Nature’ showing that the treatment resistance of metastatic castration-resistant prostate cancer can be overcome by preventing white blood cells from being kidnapped into the tumor.
Metastatic castration-resistant prostate cancer is advanced prostate cancer that does not respond to normal treatment and has spread to other organs, with an estimated survival time of only 9 months to 3 years. Unlike general prostate cancer, which grows dependent on testosterone, castration-resistant prostate cancer continues to grow even after testosterone production is suppressed.
There is currently no cure for castration-resistant prostate cancer, but radiation therapy, hormone therapy, chemotherapy, and immunotherapy are being considered.
Bone marrow white blood cells normally protect the body from infection, but sometimes they are absorbed into tumors, promoting tumor growth and causing resistance to treatment.
The research team at the Institute of Cancer Research, London attempted to prevent bone marrow cells from being absorbed into tumors using AZD5069 reagent and Enzalutamide, a hormone treatment for prostate cancer.
They found that 5 of 21 patients with metastatic castration-resistant prostate cancer responded to treatment in the form of a greater than 30% reduction in tumor size, a decrease in blood prostate-specific antigen (PSA) levels, or a decrease in the number of circulating tumor cells after treatment. reported. Additionally, they added, patients who received the treatment had a decrease in bone marrow cells, and biopsies showed a low number of bone marrow cells in the tumor.
The research team was excited about the possibility of treating metastatic castration-resistant prostate cancer with treatment targeting bone marrow cells rather than tumor cells.
Furthermore, they noted that bone marrow leukocytes are known to promote tumor growth in other types of carcinoma, and predicted that treatments targeting them could be widely used in carcinomas other than castration-resistant prostate cancer.
Experts evaluated that, unlike traditional treatments that focused on the tumor cells themselves, treatments targeting the tumor microenvironment surrounding cancer cells were a very interesting and innovative approach. They cautioned that this was an early clinical trial and said that larger randomized controlled trials should be conducted.
Medical Today Reporter Jaebaek Choi ([email protected])
[저작권자ⓒ 메디컬투데이. 무단전재-재배포 금지]
1698550664
#Discovery #treatment #approach #treat #prostate #cancer #respond #treatment